Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1984 1
1985 5
1986 1
1987 12
1988 12
1989 19
1990 21
1991 22
1992 24
1993 46
1994 64
1995 68
1996 95
1997 95
1998 111
1999 109
2000 120
2001 130
2002 149
2003 164
2004 220
2005 219
2006 213
2007 295
2008 396
2009 502
2010 605
2011 782
2012 930
2013 1078
2014 1348
2015 1442
2016 1591
2017 1792
2018 2013
2019 2278
2020 2698
2021 3274
2022 3360
2023 3520
2024 4925
2025 7001
2026 5864

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42,192 results

Results by year

Filters applied: . Clear all
Page 1
Tirzepatide Use Is Associated with Reduced Risk of Carpal Tunnel Syndrome in Overweight and Obese Adults.
Su YJ, Gau SY, Shiue YL. Su YJ, et al. Clin Pharmacol Ther. 2026 Aug 10. doi: 10.1002/cpt.70440. Online ahead of print. Clin Pharmacol Ther. 2026. PMID: 42572932
This study aimed to evaluate the association between tirzepatide use and the risk of carpal tunnel syndrome (CTS) and CTS surgery compared with both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and other anti-obesity medications in indiv …
This study aimed to evaluate the association between tirzepatide use and the risk of carpal tunnel syndrome (CTS) and CTS surgery compared w …
A Systems Pharmacology Model of Aging Identifies Optimal Combination Therapies With Secondary Benefits on Weight Loss and Metabolic Health.
Goryanin I, Damms B, Goryanin I. Goryanin I, et al. CPT Pharmacometrics Syst Pharmacol. 2026 Aug;15(8):e70322. doi: 10.1002/psp4.70322. CPT Pharmacometrics Syst Pharmacol. 2026. PMID: 42572918
Bayesian meta-analysis confirmed strong metabolic effects for semaglutide, moderate glycaemic effects for SGLT2 inhibitors and metformin, and a near-zero HbA1c effect for rapamycin. Sensitivity analysis revealed largely orthogonal metabolic and aging parameter spaces. Comb …
Bayesian meta-analysis confirmed strong metabolic effects for semaglutide, moderate glycaemic effects for SGLT2 inhibitors and metfor …
Bowel Obstruction/Ileus Associated With the Use of Glucagon-Like Peptide-1 Receptor Agonists: A Nationwide Database Study.
Matsuo Y, Okada A, Sakamoto T, Yasunaga H. Matsuo Y, et al. Diabetes Obes Metab. 2026 Aug 9. doi: 10.1111/dom.71189. Online ahead of print. Diabetes Obes Metab. 2026. PMID: 42572004
AIMS: The association between glucagon-like peptide-1 receptor agonist (GLP-1RA) use and the development of bowel obstruction/ileus remains unclear, and evidence for specific bowel obstruction/ileus subtypes remains limited. ...
AIMS: The association between glucagon-like peptide-1 receptor agonist (GLP-1RA) use and the development …
Glucagon-Like Peptide-1 Receptor Agonists and Related Incretin Therapies in Dermatology: Patient Selection and Shared Decision-Making.
Ndubisi S, Lio P. Ndubisi S, et al. Clin Dermatol. 2026 Aug 9:S0738-081X(26)00215-4. doi: 10.1016/j.clindermatol.2026.08.005. Online ahead of print. Clin Dermatol. 2026. PMID: 42571802
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and related incretin therapies have moved rapidly from second-line diabetes agents to widely prescribed cardiometabolic medications, and dermatologists increasingly encounter patients who are …
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and related incretin therapies have moved rapidly f …
Effects of pharmacological blood pressure lowering in heart failure with mildly reduced or preserved ejection fraction: a meta-analysis.
Pack SJJ, Sawant S, Abhayaratna C, Wang N. Pack SJJ, et al. Heart. 2026 Aug 7:heartjnl-2026-327872. doi: 10.1136/heartjnl-2026-327872. Online ahead of print. Heart. 2026. PMID: 42571647
Pharmacological BP lowering led to a significant reduction in the primary composite endpoint (RR 0.86, 95% CI 0.83 to 0.89; p 0.001), but there were significant differences between drug classes (p value=0.018), with evidence of benefit with sodium-glucose cotransporter 2 inhibito …
Pharmacological BP lowering led to a significant reduction in the primary composite endpoint (RR 0.86, 95% CI 0.83 to 0.89; p 0.001), but th …
42,192 results
You have reached the last available page of results. Please see the User Guide for more information.